High-risk HPV type-specific clearance rates in cervical screening

N W J Bulkmans, J Berkhof, S Bulk, M C G Bleeker, F J van Kemenade, L Rozendaal, P J F Snijders, C J L M Meijer, POBASCAM Study Group

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

We assessed clearance rates of 14 high-risk human papillomavirus (hrHPV) types in hrHPV-positive women with normal cytology and borderline/mild dyskaryosis (BMD) in a population-based cervical screening cohort of 44,102 women. The 6-month hrHPV type-specific clearance rates, that is, clearance of the same type as detected at baseline, in women with normal and BMD smears were 43% (95% confidence interval (CI) 39-47) and 29% (95% CI 24-34), respectively. Corresponding 18-month clearance rates were markedly higher, namely 65% (95% CI 60-69) and 41% (95% CI 36-47), respectively. The lowest clearance rates in women with normal cytology were observed for HPV16, HPV18, HPV31, and HPV33. Significantly reduced 18-month clearance rates at a significance level of 1% were observed for HPV16 (49%, 95% CI 41-59) and HPV31 (50%, 95% CI 39-63) in women with normal cytology, and for HPV16 (19%, 95% CI 12-29) in women with BMD. Among women who did not clear hrHPV, women with HPV16 persistence displayed an increased detection rate of >or=CIN3 (normal P<0.0001; BMD, P=0.005). The type-specific differences in clearance rates indicate the potential value of hrHPV genotyping in screening programs. Our data support close surveillance (i.e. referral directly, or within 6 months) of women with HPV16 and are inconclusive for surveillance of women with HPV18, HPV31, and HPV33. For the other hrHPV-positive women, it seems advisable to adopt a conservative management with a long waiting period, as hrHPV clearance is markedly higher after 18 months than after 6 months and the risk for >or=CIN3 is low.

Original languageEnglish
Pages (from-to)1419-24
Number of pages6
JournalBritish Journal of Cancer
Volume96
Issue number9
DOIs
Publication statusPublished - 7 May 2007

Cite this

Bulkmans, N. W. J., Berkhof, J., Bulk, S., Bleeker, M. C. G., van Kemenade, F. J., Rozendaal, L., ... POBASCAM Study Group (2007). High-risk HPV type-specific clearance rates in cervical screening. British Journal of Cancer, 96(9), 1419-24. https://doi.org/10.1038/sj.bjc.6603653
Bulkmans, N W J ; Berkhof, J ; Bulk, S ; Bleeker, M C G ; van Kemenade, F J ; Rozendaal, L ; Snijders, P J F ; Meijer, C J L M ; POBASCAM Study Group. / High-risk HPV type-specific clearance rates in cervical screening. In: British Journal of Cancer. 2007 ; Vol. 96, No. 9. pp. 1419-24.
@article{7c33197f59de43ad95109dca1471e958,
title = "High-risk HPV type-specific clearance rates in cervical screening",
abstract = "We assessed clearance rates of 14 high-risk human papillomavirus (hrHPV) types in hrHPV-positive women with normal cytology and borderline/mild dyskaryosis (BMD) in a population-based cervical screening cohort of 44,102 women. The 6-month hrHPV type-specific clearance rates, that is, clearance of the same type as detected at baseline, in women with normal and BMD smears were 43{\%} (95{\%} confidence interval (CI) 39-47) and 29{\%} (95{\%} CI 24-34), respectively. Corresponding 18-month clearance rates were markedly higher, namely 65{\%} (95{\%} CI 60-69) and 41{\%} (95{\%} CI 36-47), respectively. The lowest clearance rates in women with normal cytology were observed for HPV16, HPV18, HPV31, and HPV33. Significantly reduced 18-month clearance rates at a significance level of 1{\%} were observed for HPV16 (49{\%}, 95{\%} CI 41-59) and HPV31 (50{\%}, 95{\%} CI 39-63) in women with normal cytology, and for HPV16 (19{\%}, 95{\%} CI 12-29) in women with BMD. Among women who did not clear hrHPV, women with HPV16 persistence displayed an increased detection rate of >or=CIN3 (normal P<0.0001; BMD, P=0.005). The type-specific differences in clearance rates indicate the potential value of hrHPV genotyping in screening programs. Our data support close surveillance (i.e. referral directly, or within 6 months) of women with HPV16 and are inconclusive for surveillance of women with HPV18, HPV31, and HPV33. For the other hrHPV-positive women, it seems advisable to adopt a conservative management with a long waiting period, as hrHPV clearance is markedly higher after 18 months than after 6 months and the risk for >or=CIN3 is low.",
keywords = "Adult, Alphapapillomavirus, Cervix Uteri, Female, Humans, Mass Screening, Middle Aged, Papillomavirus Infections, Uterine Cervical Neoplasms, Vaginal Smears, Journal Article, Research Support, Non-U.S. Gov't",
author = "Bulkmans, {N W J} and J Berkhof and S Bulk and Bleeker, {M C G} and {van Kemenade}, {F J} and L Rozendaal and Snijders, {P J F} and Meijer, {C J L M} and {POBASCAM Study Group}",
year = "2007",
month = "5",
day = "7",
doi = "10.1038/sj.bjc.6603653",
language = "English",
volume = "96",
pages = "1419--24",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "9",

}

High-risk HPV type-specific clearance rates in cervical screening. / Bulkmans, N W J; Berkhof, J; Bulk, S; Bleeker, M C G; van Kemenade, F J; Rozendaal, L; Snijders, P J F; Meijer, C J L M; POBASCAM Study Group.

In: British Journal of Cancer, Vol. 96, No. 9, 07.05.2007, p. 1419-24.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - High-risk HPV type-specific clearance rates in cervical screening

AU - Bulkmans, N W J

AU - Berkhof, J

AU - Bulk, S

AU - Bleeker, M C G

AU - van Kemenade, F J

AU - Rozendaal, L

AU - Snijders, P J F

AU - Meijer, C J L M

AU - POBASCAM Study Group

PY - 2007/5/7

Y1 - 2007/5/7

N2 - We assessed clearance rates of 14 high-risk human papillomavirus (hrHPV) types in hrHPV-positive women with normal cytology and borderline/mild dyskaryosis (BMD) in a population-based cervical screening cohort of 44,102 women. The 6-month hrHPV type-specific clearance rates, that is, clearance of the same type as detected at baseline, in women with normal and BMD smears were 43% (95% confidence interval (CI) 39-47) and 29% (95% CI 24-34), respectively. Corresponding 18-month clearance rates were markedly higher, namely 65% (95% CI 60-69) and 41% (95% CI 36-47), respectively. The lowest clearance rates in women with normal cytology were observed for HPV16, HPV18, HPV31, and HPV33. Significantly reduced 18-month clearance rates at a significance level of 1% were observed for HPV16 (49%, 95% CI 41-59) and HPV31 (50%, 95% CI 39-63) in women with normal cytology, and for HPV16 (19%, 95% CI 12-29) in women with BMD. Among women who did not clear hrHPV, women with HPV16 persistence displayed an increased detection rate of >or=CIN3 (normal P<0.0001; BMD, P=0.005). The type-specific differences in clearance rates indicate the potential value of hrHPV genotyping in screening programs. Our data support close surveillance (i.e. referral directly, or within 6 months) of women with HPV16 and are inconclusive for surveillance of women with HPV18, HPV31, and HPV33. For the other hrHPV-positive women, it seems advisable to adopt a conservative management with a long waiting period, as hrHPV clearance is markedly higher after 18 months than after 6 months and the risk for >or=CIN3 is low.

AB - We assessed clearance rates of 14 high-risk human papillomavirus (hrHPV) types in hrHPV-positive women with normal cytology and borderline/mild dyskaryosis (BMD) in a population-based cervical screening cohort of 44,102 women. The 6-month hrHPV type-specific clearance rates, that is, clearance of the same type as detected at baseline, in women with normal and BMD smears were 43% (95% confidence interval (CI) 39-47) and 29% (95% CI 24-34), respectively. Corresponding 18-month clearance rates were markedly higher, namely 65% (95% CI 60-69) and 41% (95% CI 36-47), respectively. The lowest clearance rates in women with normal cytology were observed for HPV16, HPV18, HPV31, and HPV33. Significantly reduced 18-month clearance rates at a significance level of 1% were observed for HPV16 (49%, 95% CI 41-59) and HPV31 (50%, 95% CI 39-63) in women with normal cytology, and for HPV16 (19%, 95% CI 12-29) in women with BMD. Among women who did not clear hrHPV, women with HPV16 persistence displayed an increased detection rate of >or=CIN3 (normal P<0.0001; BMD, P=0.005). The type-specific differences in clearance rates indicate the potential value of hrHPV genotyping in screening programs. Our data support close surveillance (i.e. referral directly, or within 6 months) of women with HPV16 and are inconclusive for surveillance of women with HPV18, HPV31, and HPV33. For the other hrHPV-positive women, it seems advisable to adopt a conservative management with a long waiting period, as hrHPV clearance is markedly higher after 18 months than after 6 months and the risk for >or=CIN3 is low.

KW - Adult

KW - Alphapapillomavirus

KW - Cervix Uteri

KW - Female

KW - Humans

KW - Mass Screening

KW - Middle Aged

KW - Papillomavirus Infections

KW - Uterine Cervical Neoplasms

KW - Vaginal Smears

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

U2 - 10.1038/sj.bjc.6603653

DO - 10.1038/sj.bjc.6603653

M3 - Article

VL - 96

SP - 1419

EP - 1424

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 9

ER -